Syros Pharmaceuticals (NASDAQ:SYRS) Earns Neutral Rating from HC Wainwright

Syros Pharmaceuticals (NASDAQ:SYRS - Get Free Report)'s stock had its "neutral" rating reaffirmed by analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $1.00 target price on the stock, down from their previous target price of $6.00. HC Wainwright's price objective points to a potential upside of 177.78% from the company's previous close.

A number of other analysts have also recently issued reports on SYRS. JMP Securities reduced their target price on shares of Syros Pharmaceuticals from $12.00 to $4.00 and set a "market outperform" rating for the company in a research note on Tuesday, August 13th. Piper Sandler reaffirmed an "overweight" rating and issued a $5.00 price objective (down previously from $13.00) on shares of Syros Pharmaceuticals in a research note on Tuesday, August 13th. StockNews.com lowered Syros Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, November 4th. Finally, TD Cowen reiterated a "hold" rating on shares of Syros Pharmaceuticals in a research note on Wednesday. One analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, Syros Pharmaceuticals presently has a consensus rating of "Hold" and a consensus target price of $3.33.

Syros Pharmaceuticals Stock Down 86.8 %

SYRS traded down $2.37 on Wednesday, reaching $0.36. 37,518,992 shares of the company traded hands, compared to its average volume of 457,067. The company has a market cap of $9.66 million, a price-to-earnings ratio of -0.12 and a beta of 1.59. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.25 and a quick ratio of 2.25. The stock's 50 day moving average price is $2.04 and its 200-day moving average price is $3.85. Syros Pharmaceuticals has a 52-week low of $0.35 and a 52-week high of $8.17.

Syros Pharmaceuticals (NASDAQ:SYRS - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.08. During the same period in the previous year, the business earned ($1.35) EPS. On average, sell-side analysts expect that Syros Pharmaceuticals will post -2.94 EPS for the current fiscal year.

Insider Buying and Selling at Syros Pharmaceuticals

In other Syros Pharmaceuticals news, CEO Conley Chee acquired 50,000 shares of Syros Pharmaceuticals stock in a transaction dated Tuesday, September 10th. The stock was bought at an average cost of $1.51 per share, with a total value of $75,500.00. Following the completion of the transaction, the chief executive officer now owns 72,504 shares of the company's stock, valued at $109,481.04. The trade was a 200.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Conley Chee bought 50,000 shares of Syros Pharmaceuticals stock in a transaction that occurred on Tuesday, September 10th. The stock was acquired at an average price of $1.51 per share, for a total transaction of $75,500.00. Following the completion of the purchase, the chief executive officer now owns 72,504 shares in the company, valued at approximately $109,481.04. This represents a 200.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Jason Haas purchased 45,344 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were purchased at an average price of $1.68 per share, for a total transaction of $76,177.92. Following the completion of the purchase, the chief financial officer now directly owns 124,552 shares of the company's stock, valued at approximately $209,247.36. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 130,707 shares of company stock valued at $206,491 in the last 90 days. 12.26% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Kennedy Capital Management LLC acquired a new position in shares of Syros Pharmaceuticals in the 1st quarter valued at $2,166,000. Vanguard Group Inc. increased its stake in Syros Pharmaceuticals by 21.3% in the first quarter. Vanguard Group Inc. now owns 928,046 shares of the company's stock valued at $4,965,000 after acquiring an additional 163,234 shares during the period. Virtu Financial LLC acquired a new position in Syros Pharmaceuticals in the first quarter worth about $64,000. Acadian Asset Management LLC bought a new position in Syros Pharmaceuticals during the first quarter worth about $91,000. Finally, Certuity LLC acquired a new stake in Syros Pharmaceuticals during the second quarter valued at approximately $109,000. 91.47% of the stock is owned by institutional investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.